Dr. Markman on Timing of BSO in Patients With Ovarian Cancer

Video

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer should undergo a bilateral salpingo-oophorectomy (BSO).

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer, or at an increased risk for the disease, should undergo a bilateral salpingo-oophorectomy (BSO).

There is less definitive data on when it is appropriate for patients to undergo a BSO, Markman explains, though the likely age range is between 35 and 45 years old. It may be more fitting to have the procedure at a later age due to side effects associated with BSO, such as surgical menopause, heart disease, osteoporosis, and psychosocial issues.

Additionally, there is increasing evidence that patients with BRCA1/2 mutations will have a very different lifetime risk of ovarian cancer, Markman adds.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD